Dissemination of pediatric information resulting from pediatric studies done pursuant to FDAAA
Similar Posts
FDA In Brief: FDA issues draft guidance to foster oncology product development for pediatric populations
FDA issues draft guidance document, “FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act.” The draft guidance addresses early planning for pediatric evaluation of certain molecularly targeted oncology drugs.Melcare Biomedical Pty Ltd – 717968 – 10/09/2025
Nonprescription/OTC.”Safe Use Initiative – Current Projects
Part of Safe Use Initiative
(updated)Clinical Outcome Assessments (COA) Qualification Program Submissions
Clinical Outcome Assessments (COA) Qualification Program SubmissionsEco-NAMs Webinar Series | State of the Science for Bioaccumulation: An Integrated, Weight of Evidence Approach – 09/10/2025
The webinar will feature presentations by Dr. Pippa Curtis-Jackson, Senior Specialist at the Chemical Assessment Unit, UK EA, and Dr. Michelle Embry, Deputy Director of HESI.Clinical Outcome Assessment (COA): Frequently Asked Questions
Clinical Outcome Assessments (COA) Frequently Asked Questions